地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:18771149750
邮箱:sales@amyjet.com

艾美捷科技有限公司代理Complement Technology全系列产品。
Complement Technology公司致力于为生物医学研究提供最高质量的补体试剂。Complement Tech的研发人员在补体相关试剂领域拥有80多年的丰富经验,是补体试剂的原始制造商。
Complement Technology公司的主要产品包括:
| Purified Proteins | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| C1 (Pure) | A098 | 0.2 | 200 |
| C1q | A099 | 1 | 1000 |
| C1q (40% Glycerol) | A100 | 1 | 1000 |
| C1r Proenzyme | A101 | 0.5 | 100 |
| C1r Enzyme | A102 | 1 | 250 |
| C1s Proenzyme | A103 | 1 | 250 |
| C1s Enzyme | A104 | 1 | 250 |
| C1 Esterase Inhibitor | A140 | 1 | 1000 |
| C1s-C1INH Complex *(NEW)* | C1040 | 0.5 | 50 |
| C2 | A112 | 0.5 | 50 |
| C3 | A113 | 1 | 250 |
| C3 (concentrated) | A113c | 5 | 1000 |
| C3a | A118 | 0.5 | 50 |
| C3a desArg | A119 | 0.5 | 50 |
| C3b | A114 | 1 | 250 |
| iC3b | A115 | 1 | 250 |
| C3c | A116 | 1 | 250 |
| C3d | A117 | 1 | 100 |
| C4 | A105 | 1 | 250 |
| C4 (concentrated) | A105c | 4 | 1000 |
| C4a | A106 | 0.5 | 50 |
| C4a desArg | A107 | 0.5 | 50 |
| C4b | A108 | 1 | 250 |
| C4b Binding Protein | A109 | 1 | 250 |
| C5 | A120 | 1 | 250 |
| C5a | A144 | 0.5 | 30 |
| C5a (300) | A144(300) | 0.5 | 300 |
| C5a desArg | A145 | 0.5 | 50 |
| C5b,6 | A122 | 0.2 | 50 |
| C6 | A123 | 1 | 250 |
| C7 | A124 | 1 | 250 |
| C8 | A125 | 1 | 250 |
| C9 | A126 | 1 | 250 |
| SC5b-9 Complex | A127 | 1 | 100 |
| Factor B | A135 | 1 | 250 |
| Factor D | A136 | 0.1 | 25 |
| Factor H | A137 | 1 | 250 |
| Factor H (conc.) | A137c | 10 | 10000 |
| Factor I | A138 | 1 | 100 |
| Factor P (Properdin) | A139 | 1 | 100 |
| Cobra Venom Factor (USA Only) | A150 | 1 | 1000 |
| Factor Ba | A154 | 1 | 100 |
| Factor Bb | A155 | 1 | 250 |
| Animal Proteins | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| Cyno C3 (USA Only) | CY113 | 1 | 100 |
| Cyno C3b (USA Only) | CY114 | 1 | 100 |
| Mouse C1q | M099 | 1 | 100 |
| Mouse C3 | M113 | 1 | 100 |
| Mouse C3b | M114 | 1 | 100 |
| Rat C1q | R099 | 1 | 100 |
| See Polyclonal Antisera page for Anti-Mouse C3 | M213 | - | - |
| Anaphylatoxin | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| C3a | A118 | 0.5 | 50 |
| C3a desArg | A119 | 0.5 | 50 |
| C4a | A106 | 0.5 | 50 |
| C4a desArg | A107 | 0.5 | 50 |
| C5a | A144 | 0.5 | 30 |
| C5a desArg | A145 | 0.5 | 50 |
| C5a (300) | A144(300) | 0.5 | 300 |
| Complement Assay Reagents | |||
| 产品名称 | 货号 | 体积 | |
| GVBo (without Ca and Mg) - 250ml | B103 | 250ml | |
| GVBo (without Ca and Mg) - 1L | B101 | 1 Liter | |
| GVB++ (with Ca and Mg) - 250ml | B102 | 250ml | |
| GVB++ (with Ca and Mg) - 1L | B100 | 1 Liter | |
| GVBE (with EDTA) - 250ml | B104 | 250ml | |
| GVBE (with EDTA) - 1L | B105 | 1 Liter | |
| SGVB++ (low ionic strength w/Sucrose, Ca and Mg) - 250ml | B110 | 250ml | |
| SGVB++(low ionic strength w/Sucrose, Ca and Mg) - 1L | B111 | 1 Liter | |
| VBS++ (with Ca and Mg) - 250ml | B112 | 250ml | |
| VBS++ (with Ca and Mg) - 1L | B113 | 1 Liter | |
| EA (Ab-sensitized sheep E) - 5ml | B200 | 5ml @ 5x10⁸/ml | |
| EA (Ab-sensitized sheep E) - 10ml | B201 | 10ml @ 5x10⁸/ml | |
| EA (Ab-sensitized sheep E) - 20ml | B202 | 20ml @ 5x10⁸/ml | |
| Es (sheep E) | B210 | 20ml @ 5x10⁸/ml | |
| Er (rabbit E) - 5ml | B300 | 5ml @ 5x10⁸ml | |
| Er (rabbit E) - 10ml | B301 | 5ml @ 5x10⁸/ml | |
| Er (rabbit E) - 20ml | B302 | 20ml @ 5x10⁸/ml | |
| Zymosan (preactivated) | B400 | 10ml @ 1x10⁹/ml | |
| MgEGTA | B106 | 10ml @ 0.1M | |
| MCAR | B250 | 1.0 ml | |
| Hemolysin | Hemolysin | 2.0 ml | |
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Complement Technology"> Complement Technology

艾美捷科技代理SeraCare对照及参比物质。
艾美捷科技有限公司,自2018年与SeraCare(现隶属于LGC Clinical Diagnostics)合作以来,长期为中国客户提供包括SeraSeq系列参比物质,领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质,可以用于任何研发阶段,以确保临床基因组学检测结果的准确性。
SeraCare参比物质涵盖的范围:
1)Next Generation Sequencing
2)Sanger Sequencing
3)Real-time PCR and digital PCR (dPCR)
4)Microarray
主要特点
1)Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, and RNA fusions
2)Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs
3)Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA in plasma, and FFPE
4)Manufactured in cGMP-compliant, ISO 13485-certified facilities
5)Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers
| 参比物质 | 货号 | 规格 |
| Seraseq® Whole Transcriptome RNA Seq Mix | 0710-2129 | 1 x 20 µl |
| Seraseq® Unmethylated ctDNA Mutation Mix | 0710-3088 | 1 x 25 µl |
| Seraseq® Tumor Mutation DNA Mix v2 AF 7 HC | 0710-0095 | 1 x 25 µl |
| Seraseq® Tumor Mutation DNA Mix v2 AF 10 HC | 0710-0094 | 1 x 25 µl |
| Seraseq® Tri-Level Tumor Mutation DNA Mix v2 HC | 0710-0097 | 1 x 25 µl |
| Seraseq® TNA (DNA/RNA) WT Mix | 0710-1580 | 2 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +6 copies | 0710-2867 | 1 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +3 copies | 0710-2866 | 1 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +12 copies | 0710-2868 | 1 x 20 µl |
| Seraseq® NTRK Fusion RNA Mix | 0710-1696 | 1 x 20 µl |
| Seraseq® Myeloid Mutation DNA Mix | 0710-0408 | 1 x 25 µl |
| Seraseq® Myeloid Fusion RNA Mix | 0710-0407 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix WT | 0710-2646 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF1% | 0710-2649 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF0.5% | 0710-2648 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF0.1% | 0710-2647 | 1 x 25 µl |
| Seraseq® MSI Reference Panel Mix AF5% | 0710-1675 | 2 x 15 µl |
| Seraseq® MSI Reference Panel Mix AF20% | 0710-1676 | 2 x 15 µl |
| Seraseq® Methylated ctDNA Mutation Mix | 0710-3089 | 1 x 25 µl |
| Seraseq® Lymphoma DNA Mutation Mix | 0710-2203 | 1 x 25 µl |
| Seraseq™ Lung & Brain CNV Mix, + 6 copies | 0710-0415 | 1 x 20 µl |
| Seraseq® Lung & Brain CNV Mix, + 3 copies | 0710-0414 | 1 x 20 µl |
| Seraseq® Lung & Brain CNV Mix, + 12 copies | 0710-0416 | 1 x 20 µl |
| Seraseq® HRD gDNA Negative Mix | 0710-2881 | 2 x 20 µl |
| Seraseq® HRD gDNA Low-Positive Mix | 0710-2880 | 2 x 20 µl |
| Seraseq® HRD gDNA High-Positive Mix | 0710-2879 | 2 x 20 µl |
| Seraseq® gDNA TMB Reference Panel Mix | 0710-2463 | 5 x 20 µl |
| Seraseq® gDNA TMB Mix Score 9 | 0710-1325 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 7 | 0710-1326 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 26 | 0710-1323 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 20 | 0710-1324 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 13 | 0710-1586 | 2 x 10 µl |
| Seraseq® gDNA MSI-High Mix | 0710-1670 | 1 x 20 µl |
| Seraseq® gDNA BRCA1/2 LGR Somatic Mutation Mix | 0730-0567 | 1 x 25 µl |
| Seraseq® gDNA BRCA1/2 LGR Inherited Mutation Mix | 0730-0568 | 1 x 25 µl |
| Seraseq® Fusion RNA Mix v4 | 0710-0497 | 1 x 25 µl |
| Seraseq® FFPE WT (DNA/RNA) Reference Material | 0710-0137 | 1 x 10 µm |
| Seraseq® FFPE TMB RM Score 9 | 0710-1308 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 7 | 0710-1310 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 26 | 0710-1307 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 20 | 0710-1309 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 13 | 0710-1618 | 2 x 10 um |
| Seraseq® FFPE Solid Tumor CNV Reference Materials | 0710-2865 | 1 x 10 µm |
| Seraseq® FFPE NTRK Fusion RNA Reference Material | 0710-1031 | 1 x 10 µm |
| Seraseq® FFPE MSI-High RM | 0710-2236 | 1 x 10 um |
| Seraseq® FFPE Lymphoma DNA Reference Material | 0710-2202 | 1 x 10 µm |
| Seraseq® FFPE HRD Negative RM | 0710-2644 | 1 x 10 µm |
| Seraseq® FFPE HRD Low-Positive RM | 0710-2645 | 1 x 10 µm |
| Seraseq® FFPE HRD High-Positive RM | 0710-2643 | 1 x 10 µm |
| Seraseq® FFPE Tumor Fusion RNA v4 Reference Material | 0710-0496 | 1 x 10 µm |
| Seraseq® FFPE BRCA1/2 LGR Reference Material | 0730-0564 | 1 x 10 µm |
| Seraseq® ctDNA Reference Material v2 WT | 0710-0208 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF2% | 0710-0203 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF1% | 0710-0204 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF0.5% | 0710-0205 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF0.125% | 0710-0207 | 1 x 5 mL |
| Seraseq® ctDNA Mutation Mix v2 WT | 0710-0144 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF2% | 0710-0139 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF1% | 0710-0140 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.5% | 0710-0141 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.25% | 0710-0142 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.125% | 0710-0143 | 1 x 25 µl |
| Seraseq® ctDNA MRD Panel Mix | 0710-2146 | 4 x 20 µl |
| Seraseq® ctDNA Complete™ Reference Material WT (0%) | 0710-0674 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF5% | 0710-0669 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF2.5% | 0710-0670 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF1% | 0710-0671 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF0.5% | 0710-0672 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF0.1% | 0710-0673 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Mutation Mix WT (0%) | 0710-0533 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF5% | 0710-0528 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF2.5% | 0710-0529 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF1% | 0710-0530 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF0.5% | 0710-0531 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF0.1% | 0710-0532 | 1 x 25 µl |
| Seraseq® Compromised FFPE WT (DNA/RNA) RM | 0710-1710 | 1 x 10 µm |
| Seraseq® Compromised FFPE Tumor DNA RM | 0710-1492 | 1 x 10 µm |
| Seraseq® Breast CNV Mix, + 6 copies | 0710-0412 | 1 x 20 µl |
| Seraseq® Breast CNV Mix, + 3 copies | 0710-0411 | 1 x 20 µl |
| Seraseq® Breast CNV Mix, + 12 copies | 0710-0413 | 1 x 20 µl |
| Seraseq® Blood TMB Mix Score 7 | 0710-2087 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 26 | 0710-2090 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 20 | 0710-2089 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 13 | 0710-2088 | 3 x 20 µl |
| Seraseq® Turner Syndrome (XO) Reference Material | 0720-0952 | 1 x 1 mL |
| Seraseq® Trisomy 21 Male-Matched Reference Material | 0720-0167 | 1 x 1 mL |
| Seraseq® Trisomy 21 Female-Matched Reference Material | 0720-0168 | 1 x 1 mL |
| Seraseq® Trisomy 18 Male-Matched Reference Material | 0720-0171 | 1 x 1 mL |
| Seraseq® Trisomy 18 Female-Matched Reference Material | 0720-0172 | 1 x 1 mL |
| Seraseq® Trisomy 13 Male-Matched Reference Material | 0720-0779 | 1 x 1 mL |
| Seraseq® Trisomy 13 Female-Matched Reference Material | 0720-0780 | 1 x 1 mL |
| Seraseq® Triple X Syndrome (XXX) Reference Material | 0720-1069 | 1 x 1 mL |
| Seraseq® PGT-A Trisomy 21 Reference Material | 0720-0775 | 1 x 10 µl |
| Seraseq® PGT-A Trisomy 18 Reference Material | 0720-0776 | 1 x 10 µl |
| Seraseq® PGT-A Trisomy 13 Reference Material | 0720-0777 | 1 x 10 µl |
| Seraseq® PGT-A Euploid Reference Material | 0720-0778 | 1 x 10 µl |
| Seraseq® Klinefelter Syndrome (XXY) Reference Material | 0720-0953 | 1 x 1 mL |
| Seraseq® Jacobs Syndrome (XYY) Reference Material | 0720-0954 | 1 x 1 mL |
| Seraseq® Euploid Male-Matched Reference Material | 0720-0169 | 1 x 1 mL |
| Seraseq® Euploid Female-Matched Reference Material | 0720-0170 | 1 x 1 mL |
| Seraseq® 22q11 Male-Matched Reference Material | 0720-0173 | 1 x 1 mL |
| Seraseq® 22q11 Female-Matched Reference Material | 0720-0174 | 1 x 1 mL |
| Seraseq® Inherited Cancer DNA Mix v1 | 0730-0003 | 1 x 200 µL |
| Seraseq® gDNA BRCA1/2 LGR Inherited Mutation Mix | 0730-0568 | 1 x 25 µL |
| Seraseq® FFPE BRCA1/2 LGR Reference Material | 0730-0564 | 1 x 10 µm |
| Seraseq® Cardiomyopathy Reference Material | 0740-0021 | 1 x 200 µL |

艾美捷科技特约代理Athens Research & Technology产品。
Athens Research & Technology公司位于美国乔治亚州雅典市,从1986年以来一直致力于纯化高纯度,高活性的人类蛋白质和开发这些蛋白的多克隆抗血清。常规产品包括丝氨酸蛋白酶、蛋白酶抑制剂、中性粒细胞酶、载脂蛋白、脂蛋白,血小板蛋白、转铁蛋白、免疫球蛋白等。
Athens Research & Technology Inc. has been purifying human proteins and developing polyclonal antisera to those proteins since 1986. We specialize in highly pure, highly active human proteins. We routinely purify serine proteases, protease inhibitors, neutrophil enzymes, apolipoproteins, lipoproteins, platelet proteins, transferrins, immunoglobulins, and more. Researchers around the world have been purchasing these research reagents from us for more than twenty-five years. You'll see our products referenced in major scientific publications in studies of inflammation, coronary disease, autoimmune disease, cancer, Alzheimer's Disease, and so on.
Athens Research & Technology公司的主要产品包括:
Coagulation Factors
Enzymes & Inhibitors
Immunoglobulins
Lipoproteins & Apolipoproteins
Low Endotoxin Level Proteins
Milk & Platelet Proteins
Neutrophil Proteins
Transferrins & Apotransferrins
Transport/Other Proteins
All Human Proteins
All Animal Proteins
Antibodies
Assay Kits
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Athens Research & Technology"> Athens Research & Technology
成立27年来,PBL Assay Science一直协助工业界、学术界、政府研究人员开发检测方法和解决蛋白定量问题。PBL Assay Science的产品包括高品质、高灵敏度的ELISA试剂盒、干扰素蛋白和抗体等,此外PBL Assay Science还提供超灵敏细胞因子检测服务等。
Now entering our 27th year, PBL Assay Science works hand in hand with industry, academic, and government researchers to help solve difficult assay development and protein quantification problems. Known as a trusted source for high quality, high sensitivity ELISAs as well as interferon proteins and antibodies, PBL has expanded our assay services capabilities, including ultrasensitive cytokine detection services, and increased our human cell-expressed cytokine and growth factor offerings.
PBL Assay Science的主要产品包括:
(1)Assay Kits(ELISAs;Multiplex Assays;Cell-Based Assays)
(2)Proteins(Interferons,Cytokines and Growth Factors,Interferon Decoy Receptor)
(3)Antibodies(Monoclonal Antibodies (MAbs);Polyclonal Antibodies (PAbs))
(4)Assay Services(Quantitative Immunoassays;Cell-Based Services;Reagent Development)
| Assay Kits产品列表 |
| 品名 | 货号 | 规格 |
| iLite Human Type I IFN Responsive Cells | 51100 | 2.5 ml/vial |
| Human IFN-Alpha Multi-Subtype ELISA Kit (Serum, Plasma, TCM) | 41110-1 | 1 x 96-well plate |
| Human IFN-Alpha Multi-Subtype ELISA Kit (Serum, Plasma, TCM) | 41110-2 | 5 x 96-well plates |
| Human IFN-Alpha Multi-Subtype ELISA Kit (TCM) | 41105-1 | 1 x 96-well plate |
| Human IFN-Alpha Multi-Subtype ELISA Kit (TCM) | 41105-2 | 5 x 96-well plates |
| Human IFN-Alpha ELISA Kit (TCM) | 41100-1 | 1 x 96-well plate |
| Human IFN-Alpha ELISA Kit (TCM) | 41100-2 | 5 x 96-well plates |
| Human IFN-Alpha All Subtype ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 41115-1 | 1 x 96-well plate |
| Human IFN-Alpha All Subtype ELISA Kit, High Sensitivity (TCM) | 41135-1 | 1 x 96-well plate |
| Human IFN-Beta ELISA Kit | 41410-1 | 1 x 96-well plate |
| Human IFN-Beta ELISA Kit | 41410-2 | 5 x 96-well plates |
| Human IFN-Beta TCM ELISA, High Sensitivity | 41435-1 | 1 x 96-well plate |
| Human IFN-Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 41415-1 | 1 x 96-well plate |
| Human IFNGR1 ELISA Kit (Serum, Plasma, Cell Lysate, TCM) | 41580 | 1 x 96-well plate |
| DIY Human IFN-Lambda 1/2/3 (IL-29/28A/28B) ELISA (TCM) | 61840-1 | Materials for 15 x 96-wells |
| DIY Human IFN-Lambda 2/3 (IL-28A/B) ELISA (TCM) | 61830-1 | Materials for 15 x 96-wells |
| Mouse IFN-Alpha All Subtype ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 42115-1 | 1 x 96-well plate |
| Mouse IFN-Alpha ELISA Kit (TCM) | 42120-1 | 1 x 96-well plate |
| Mouse IFN-Alpha ELISA Kit (TCM) | 42120-2 | 5 x 96-well plates |
| Mouse IFN-Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 42410-1 | 1 x 96-well plate |
| Mouse IFN-Beta ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 42410-2 | 5 x 96-well plates |
| Mouse IFN-Beta ELISA Kit (TCM, Serum) | 42400-1 | 1 x 96-well plate |
| Mouse IFN-Beta ELISA Kit (TCM, Serum) | 42400-2 | 5 x 96-well plates |
| DIY Mouse IFN-Lambda 2/3 (IL-28A/B) ELISA (TCM) | 62830-1 | Materials for 15 x 96-wells |
| Pig IFN-Alpha ELISA Kit (Serum, Plasma, TCM) | 47100-1 | 1 x 96-well plate |
| Cynomolgus IFN-Beta ELISA Kit (Serum, Plasma, TCM) | 46415-1 | 1 x 96-well plate |
| Cynomolgus/Rhesus IFN-Alpha ELISA Kit (Serum, Plasma, TCM) | 46100-1 | 1 x 96-well plate |
| Human IL-22 ELISA, High Sensitivity (Serum, Plasma, TCM) | 41701-1 | 1 x 96-well plate |
| Total Human IL-15 ELISA Kit, High Sensitivity (Serum, Plasma, TCM) | 41702-1 | 1 x 96-well plate |
| Proteins产品列表 |
| 品名 | 货号 | 规格 |
| Human IFN-Lambda 2, Human Cell Expressed | 11720-1 | ≥ 1 x 10⁵ units |
| Human IFN-Lambda 3, Human Cell Expressed | 11730-1 | ≥ 1 x 10⁵ units |
| Human IFN-Lambda 1, Human Cell Expressed | 11725-1 | ≥ 1 x 10⁵ units |
| Human Erythropoietin (EPO), Ultrapure | 11965-1 | 500 units |
| Human Interleukin 22 (Human Cell-Expressed) | 11701-1 | 10 μg |
| Human Interleukin 22 (Human Cell-Expressed) | 11701-2 | 50 μg |
| Human Interleukin 15 / IL-15Rα Heterodimer (Human Cell-Expressed) | 11702-1 | 10 μg |
| Human Interleukin 15 / IL-15Rα Heterodimer (Human Cell-Expressed) | 11702-2 | 50 μg |
| Mouse Interferon Alpha All-Subtype Neutralizing Viral Protein | 12185-1 | 10 μg |
| Mouse Interferon Alpha All-Subtype Neutralizing Viral Protein | 12185-2 | 100 μg |
| UniversalTM Type I IFN (Human IFN-Alpha Hybrid Protein) | 11200-1 | 1 x 10⁵ units |
| UniversalTM Type I IFN (Human IFN-Alpha Hybrid Protein) | 11200-2 | 1 x 10⁶ units |
| Human IFN-Beta 1a, mammalian, carrier-free | 11410-2 | 1 x 10⁶ units |
| Human IFN-Beta (Beta 1a, Mammalian Expressed) | 11415-1 | 1 x 10⁵ units |
| Human IFN-Alpha Sampler Set | 11002-1 | 1 x 10⁵ units |
| Human IFN-Alpha 2a (Alpha A) Protein | 11100-1 | 5 x 10⁶ units |
| Human IFN-Alpha 2a (Alpha A) Protein, Carrier-Free | 11101-1 | 5 μg |
| Human IFN-Alpha 2a (Alpha A) Protein, Carrier-Free | 11101-2 | 20 μg |
| Human IFN-Alpha 2b (Alpha 2) Protein | 11105-1 | 1 x 10⁵ units |
| Human IFN-Alpha 8 (Alpha B2) Protein | 11115-1 | 1 x 10⁵ units |
| Human IFN-Alpha 10 (Alpha C) Protein | 11120-1 | 1 x 10⁵ units |
| Human IFN-Alpha 1 (Alpha D) Protein | 11125-1 | 1 x 10⁵ units |
| Human IFN-Alpha 21 (Alpha F) Protein | 11130-1 | 1 x 10⁵ units |
| Human IFN-Alpha 5 (Alpha G) Protein | 11135-1 | 1 x 10⁵ units |
| Human IFN-Alpha 14 (Alpha H2) Protein | 11145-1 | 1 x 10⁵ units |
| Human IFN-Alpha 17 (Alpha I) Protein | 11150-1 | 1 x 10⁵ units |
| Human IFN-Alpha 7 (Alpha J1) | 11160-1 | 1 x 10⁵ units |
| Human IFN-Alpha 6 (Alpha K) Protein | 11165-1 | 1 x 10⁵ units |
| Human IFN-Alpha D (Alpha 1) Protein | 11175-1 | 1 x 10⁵ units |
| Human IFN-Alpha 4a (Alpha M1) Protein | 11177-1 | 1 x 10⁵ units |
| Human IFN-Alpha 4b (Alpha 4) Protein | 11180-1 | 1 x 10⁵ units |
| Human IFN-Alpha 16 (Alpha WA) Protein | 11190-1 | 1 x 10⁵ units |
| Human IFN-Omega | 11395-1 | 25 μg |
| Human IFN-Beta 1b, E.Coli | 11420-1 | 1 x 10⁵ units |
| Human IL-28A/IFN-Lambda 2, Carrier-Free | 11821-1 | 25 μg |
| Human IL-29/IFN-Lambda 1, Carrier-Free | 11826-1 | 25 μg |
| Human IFN-Gamma | 11500-1 | 50 μg |
| Human IFN-Gamma | 11500-2 | 100 μg |
| Cynomolgus IFN-Alpha 2 (Ile 16), Mammalian | 16105-1 | 1 x 10⁵ units |
| Rhesus/Cynomolgus IFN-Alpha 2 | 14110-1 | 1 x 10⁵ units |
| Feline IFN-Alpha | 15100-1 | 1 x 10⁵ units |
| Porcine IFN-Alpha | 17105-1 | 1 x 10⁵ units |
| Bovine IFN-Tau 2, Mammalian | 19616-1 | 1 x 10⁵ units |
| Mouse IFN-Beta, Mammalian | 12405-1 | 1 x 10⁵ units |
| Mouse IFN-Beta, Mammalian, Carrier-Free | 12410-1 | 1 x 10⁶ units |
| Mouse IFN-Alpha A | 12100-1 | 1 x 10⁵ units |
| Mouse IFN-Alpha 1 | 12105-1 | 1 x 10⁵ units |
| Mouse IFN-Alpha 4, mammalian | 12115-1 | 1 x 10⁵ units |
| Mouse IFN-Alpha 11 | 12125-1 | 1 x 10⁵ units |
| Mouse IFN-Alpha 13 | 12130-1 | 1 x 10⁵ units |
| Mouse IFN-Beta, E.Coli | 12400-1 | 1 x 10⁵ units |
| Mouse IFN-Beta, Carrier-Free | 12401-1 | 1 x 10⁵ units |
| Mouse IL-28B/IFN-Lambda 3 | 12820-1 | 25 μg |
| Mouse IL-28B/IFN-Lambda 3, Carrier-Free | 12821-1 | 25 μg |
| Rat IFN-Alpha 1, Mammalian | 13101-1 | 10 μg |
| Rat IFN-Alpha 14, Mammalian | 13114-1 | 10 μg |
| Rat IFN-Alpha 1 | 13100-1 | 1 x 10⁵ units |
| Rat IFN-Beta | 13400-1 | 1 x 10⁵ units |
| Rat IFN-Gamma | 13500-1 | 10 μg |
| Antibodies产品列表 |
| 品名 | 货号 | 规格 |
| Anti-Human IFN-Alpha, Clone MMHA-2 (MAb) | 21100-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-2 (MAb) | 21100-2 | 500 μg |
| Anti-Human IFN-Alpha, Clone MMHA-1 (MAb) | 21105-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-11 (MAb) | 21112-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-13(MAb) | 21116-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-17 (MAb) | 21118-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-6 (MAb) | 21125-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-9 (MAb) | 21127-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-14 (MAb) | 21129-1 | 50 μg |
| Anti-Human IFN-Alpha, Clone MMHA-8 (MAb) | 21110-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-3 (MAb) | 21400-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-1 (MAb) | 21405-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-2 (MAb) | 21410-1 | 500 μg |
| Anti-Human IFN-Beta, Clone MMHB-12 (MAb) | 21450-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-13 (MAb) | 21455-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-14 (MAb) | 21460-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-15 (MAb) | 21465-1 | 50 μg |
| Anti-Human IFN-Beta, Clone MMHB-16 (MAb) | 21470-1 | 50 μg |
| Anti-Human IFN-Alpha/Beta Receptor 1 Antibody, Clone MMHAR-3 | 21370-1 | 50 μg |
| Anti-Human IFN-Alpha/Beta Receptor Chain 2, Clone MMHAR-2 (MAb) | 21385-1 | 50 μg |
| Anti-Human IFN-Gamma Receptor Chain 2, Clone MMHGR-2 (MAb) | 21585-1 | 250 μg |
| Anti-Human IFN-Lambda Receptor 1, Clone MMHLR-1 (MAb) | 21885-1 | 50 μg |
| Anti-Human IFN-Lambda Receptor 1, Clone HLR14 (MAb) | 21886-1 | 50 μg |
| Anti-Human IFN-Gamma, Clone MMHG-1 (MAb) | 21500-1 | 500 μg |
| Anti-Human IFN-Gamma, Clone MMHG-2 (MAb) | 21550-1 | 100 μg |
| Anti-Human IFN-Gamma Receptor Chain 2, Clone MMHGR-2 (MAb) | 21585-1 | 250 μg |
| Anti-Human IL-28A/IFNL2, neutralizing, Clone MMHL-2 (MAb) | 21720-1 | 200 μg |
| Anti-Human Interleukin-28B/Interferon Lambda 3, neutralizing, Clone MMHL-3 (MAb) | 21730-1 | 100 μg |
| Anti-Human ISG15, Clone 2.1 (MAb) | 21900-1 | 100 μg |
| Anti-Mouse IFN-Alpha, Clone RMMA-1 (MAb) | 22100-1 | 250 μg |
| FITC Conjugated Anti-Mouse IFN-Alpha, Clone RMMA-1 (MAb) | 22100-3 | 25 μg |
| Anti-Mouse IFN-Beta, Clone RMMB-1 (MAb) | 22400-1 | 250 μg |
| Anti-Mouse IFN-Gamma, Clone RMMG-1 (MAb) | 22500-1 | 500 μg |
| Anti-Pig IFN-Alpha, Clone K9 (MAb) | 27100-1 | 500 μg |
| Anti-Pig IFN-Alpha, Clone F17 (MAb) | 27105-1 | 500 μg |
| FITC Conjugated Anti-Mouse IFN-Alpha, Clone RMMA-1 (MAb) | 22100-3 | 25 μg |
| Anti-Human IFN-Alpha, Rabbit Serum (PAb) | 31101-1 | 1 x 10⁵ units |
| Anti-Human IFN-Alpha, Sheep Serum (PAb) | 31110-1 | 1 x 10⁵ units |
| Anti-Human IFN-Alpha (All Subtypes), Rabbit Serum (PAb) | 31135-1 | 1 x 10⁵ units |
| Anti-Human IFN-Beta, Sheep Serum (PAb) | 31401-1 | 2 x 10⁴ units |
| Anti-Human IFN-Beta, Rabbit IgG, protein A purified (PAb) | 31405-1 | 2 x 10⁴ units |
| Anti-Human IFN-Beta, Rabbit Serum (PAb) | 31410-1 | 2 x 10⁴ units |
| Anti-Human IFN-Beta, Goat IgG, Affinity Purified (PAb) | 31420-1 | 100 μg |
| Anti-Human IFN-Gamma, Rabbit Serum (PAb) | 31500-1 | 2 x 10⁴ units |
| Human Type I IFN Neutralizing Antibody Mixture | 39000-1 | 0.2 ml |
| Anti-Mouse IFN-Alpha, Rabbit Serum (PAb) | 32100-1 | 2 x 10⁴ units |
| Anti-Mouse IFN-Alpha, Chicken IgY, Purified (PAb) | 32120-1 | 500 μg |
| Anti-Mouse IFN-Beta, Rabbit Serum (PAb) | 32400-1 | 2 x 10⁴ units |
| Anti-Mouse IFN-Beta, Rabbit IgG, Protein A purified (PAb) | 32401-1 | 2 x 10⁴ units |
| Anti-Mouse IFN-Gamma, Rabbit Serum (PAb) | 32500-1 | 2 x 10⁴ units |
| Anti-Rat IFN-Alpha, Rabbit IgG, Protein A Purified (PAb) | 33100-1 | 500 μg |
| Anti-Rat IFN-Beta, Rabbit IgG, Protein A purified (PAb) | 33400-1 | 500 μg |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Anogen-Yes Biotech Laboratories Ltd. 创建于1989年, 位于加拿大多伦多近郊的著名高科技城市密西沙加市。Anogen是加拿大逸士生物技术研究有限公司在国际上的市场经销部门。Anogen-Yes Biotech Laboratories Ltd.研发和生产各种新颖抗体及有关产品,应用广泛的技术平台设计和开发各种单克隆抗体、多克隆抗体、基因工程/人源化抗体、免疫检验用配对抗体、免疫球蛋白、活性多肽、酶联免疫试剂盒[ELISA]、斑点酶联免疫试剂盒[Elispots]和基因重组蛋白质等等。 这些产品主要用于生命科学研究和各种疾病的诊断和防治,包括炎症和自身免疫性疾病、心血管病和癌症等。
Anogen is the trade name of Yes Biotech Laboratories Ltd., a Canadian biopharmaceutical company based in Mississauga, Ontario. Founded in 1989, Anogen-Yes Biotech specializes in developing and manufacturing monoclonal antibodies, recombinant proteins, synthetic bioactive peptides, and Enzyme linked immunosorbent assay (ELISA) kits for research as well as diagnostic and therapeutic use.[1] It is also committed to seeking medical treatment of cancer, autoimmune, inflammatory and cardiovascular diseases by developing antibody-based biopharmaceuticals.
Anogen的主要产品包括:
Monoclonal Antibodies
Polyclonal Antibodies
Matched Antibody Pairs
ELISA Kits
按照研究领域细分:
Inflammatory & Growth Factors
Cell Biology & Molecular Biology
Immunoassay Reagents
Infection & Toxin
Coagulation Factors
Hormone
Neurological Disorder
Tumor Research
| 品名 | 货号 | 规格 |
| mAb anti-Human TNF-α, CH8810 | MO-C40003A | 0.1 mg |
| mAb anti-Human TNF-α, CH8820, Capture | MO-C40003B | 0.1 mg |
| mAb anti-Human TNF-α, C2H9 | MO-C40003D | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Detector | MO-C40003E | 0.1 mg |
| mAb anti-Human TNF-α, C2A7 | MO-C40003F | 0.1 mg |
| mAb anti-Human TNF-α, C5G7 | MO-C40003G | 0.1 mg |
| mAb anti-Human TNF-α, C4C7 | MO-C40003H | 0.1 mg |
| mAb anti-Human IFN-γ, 315 | MO-C40004D | 0.1 mg |
| mAb anti-Human IFN-γ, 165 | MO-C40004E | 0.1 mg |
| mAb anti-Human IFN-γ, 23 | MO-C40004F | 0.1 mg |
| mAb anti-Human CCR1, 293 | MO-C40005A | 0.1 mg |
| mAb anti-Human TGF-β, TB21 | MO-C40009A | 0.1 mg |
| mAb anti-Human TGF-β, 2C5 | MO-C40009B | 0.1 mg |
| mAb anti-Human TGF-β, 2C6 | MO-C40009D | 0.1 mg |
| mAb anti-Human TGF-β, 2E6 | MO-C40009E | 0.1 mg |
| mAb anti-Human TGF-β, 8C4 | MO-C40009F | 0.1 mg |
| mAb anti-Human IL-8, I8-S2, Capture | MO-C40017A | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Detector | MO-C40017D | 0.1 mg |
| mAb anti-Human IL-8, I8-61 | MO-C40017E | 0.1 mg |
| mAb anti-Human IL-8, 257 | MO-C40017F | 0.1 mg |
| mAb anti-Human IL-8, 807 | MO-C40017G | 0.1 mg |
| mAb anti-Human MCP-1, S8 | MO-C40021A | 0.1 mg |
| mAb anti-Human MCP-1, S14, Capture | MO-C40021B | 0.1 mg |
| mAb anti-Human MCP-1, S101, Detector | MO-C40021D | 0.1 mg |
| mAb anti-Human MCP-1, 9G10 | MO-C40021E | 0.1 mg |
| mAb anti-Human MCP-1, S382 | MO-C40021F | 0.1 mg |
| mAb anti-Human SAA, 115, Capture | MO-C40028A | 0.1 mg |
| mAb anti-Human SAA, 513 | MO-C40028D | 0.1 mg |
| mAb anti-Human SAA, 607, Detector | MO-C40028E | 0.1 mg |
| mAb anti-Human SAA, 291 | MO-C40028G | 0.1 mg |
| mAb anti-Human SAA, 504 | MO-C40028H | 0.1 mg |
| mAb anti-Human SAA, 585 | MO-C40028J | 0.1 mg |
| mAb anti-Human SAA, 426 | MO-C40028K | 0.1 mg |
| mAb anti-Human SAA, 38 | MO-C40028L | 0.1 mg |
| mAb anti-Human SAA, 132 | MO-C40028M | 0.1 mg |
| mAb anti-Human SAA, S3 | MO-C40028N | 0.1 mg |
| mAb anti-Human IL-1β, S1H12 | MO-C40029A | 0.1 mg |
| mAb anti-Human IL-1β, S1B7 | MO-C40029B | 0.1 mg |
| mAb anti-Human IL-1β, S3F12 | MO-C40029G | 0.1 mg |
| mAb anti-Human IL-1β, 464 | MO-C40029H | 0.1 mg |
| mAb anti-Human IL-2, 5A8, | MO-C40032A | 0.1 mg |
| mAb anti-Human IL-2, 9F9, | MO-C40032B | 0.1 mg |
| mAb anti-Human IL-2, 10C4 | MO-C40032C | 0.1 mg |
| mAb anti-Human IL-2, 8C2 | MO-C40032D | 0.1 mg |
| mAb anti-Human IL-2, 6F11 | MO-C40032E | 0.1 mg |
| mAb anti-Human IL-2, 6B1 | MO-C40032F | 0.1 mg |
| mAb anti-Human EGF, S-21 | MO-C40044A | 0.1 mg |
| mAb anti-Human EGF, S-120 | MO-C40044B | 0.1 mg |
| mAb anti-Human EGF, S-134, Capture | MO-C40044D | 0.1 mg |
| mAb anti-Human EGF, S-145 | MO-C40044E | 0.1 mg |
| mAb anti-Human EGF, S-146, Detector | MO-C40044F | 0.1 mg |
| mAb anti-Human EGF, S-147 | MO-C40044G | 0.1 mg |
| mAb anti-Human EGF, S-177 | MO-C40044H | 0.1 mg |
| mAb anti-Human G-CSFR, S-1252 | MO-C40045A | 0.1 mg |
| mAb anti-Human G-CSFR, S-1268 | MO-C40045B | 0.1 mg |
| mAb anti-Human G-CSFR, S-1284 | MO-C40045D | 0.1 mg |
| mAb anti-Human G-CSFR, S-1374 | MO-C40045E | 0.1 mg |
| mAb anti-Human G-CSFR, S-425 | MO-C40045F | 0.1 mg |
| mAb anti-Human G-CSFR, S-1390 | MO-C40045G | 0.1 mg |
| mAb anti-Human bFGF, F-343 | MO-C40046A | 0.1 mg |
| mAb anti-Human bFGF, F-74 | MO-C40046B | 0.1 mg |
| mAb anti-Human bFGF, F-474 | MO-C40046F | 0.1 mg |
| mAb anti-Human bFGF, F-3 | MO-C40046H | 0.1 mg |
| mAb anti-Human EPO, 85 | MO-C40047A | 0.1 mg |
| mAb anti-Human M-CSF, 116 | MO-C40048A | 0.1 mg |
| mAb anti-Human M-CSF, 692 | MO-C40048B | 0.1 mg |
| mAb anti-Human M-CSF, 21 | MO-C40048D | 0.1 mg |
| mAb anti-Human MIP-1α, 116 | MO-C40051A | 0.1 mg |
| mAb anti-Human MIP-1α, 125 | MO-C40051D | 0.1 mg |
| mAb anti-Human MIP-1α, 548 | MO-C40051F | 0.1 mg |
| mAb anti-Human MIP-1α, 199 | MO-C40051G | 0.1 mg |
| mAb anti-Human MIP-1α, 400 | MO-C40051L | 0.1 mg |
| mAb anti-Human MIP-1α, 103 | MO-C40051M | 0.1 mg |
| mAb anti-Human MIP-1α, 376 | MO-C40051N | 0.1 mg |
| mAb anti-Human MIP-1α, 426 | MO-C40051P | 0.1 mg |
| mAb anti-Human MCP-3, 113, Detector | MO-C40088A | 0.1 mg |
| mAb anti-Human MCP-3, 343 | MO-C40088B | 0.1 mg |
| mAb anti-Human MCP-3, 490 | MO-C40088D | 0.1 mg |
| mAb anti-Human MCP-3, 768 | MO-C40088E | 0.1 mg |
| mAb anti-Human MCP-3, 1057 | MO-C40088F | 0.1 mg |
| mAb anti-Human MCP-3, 542, Capture | MO-C40088G | 0.1 mg |
| mAb anti-Human MCP-3, 1015 | MO-C40088H | 0.1 mg |
| mAb anti-Human IL-16, 59 | MO-C40089G | 0.1 mg |
| mAb anti-Human IL-16, 210 | MO-C40089H | 0.1 mg |
| mAb anti-Human IL-16, 323, Detector | MO-C40089J | 0.1 mg |
| mAb anti-Human IL-16, 398, Capture | MO-C40089K | 0.1 mg |
| mAb anti-Human IL-16, 568 | MO-C40089M | 0.1 mg |
| mAb anti-Human IL-16, 572 | MO-C40089N | 0.1 mg |
| mAb anti-Human GM-CSF, 29 | MO-C40090A | 0.1 mg |
| mAb anti-Human GM-CSF, 59, Capture | MO-C40090B | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Detector | MO-C40090D | 0.1 mg |
| mAb anti-Human GM-CSF, 204 | MO-C40090E | 0.1 mg |
| mAb anti-Human GM-CSF, 489 | MO-C40090F | 0.1 mg |
| mAb anti-Human GM-CSF, 120 | MO-C40090G | 0.1 mg |
| mAb anti-Human GM-CSF, 26 | MO-C40090H | 0.1 mg |
| mAb anti-Human GM-CSF, 174 | MO-C40090K | 0.1 mg |
| mAb anti-Human GM-CSF, S333 | MO-C40090L | 0.1 mg |
| mAb anti-Human IL-6, 2E10 | MO-C40091B | 0.1 mg |
| mAb anti-Human IL-6, 8E10 | MO-C40091C | 0.1 mg |
| mAb anti-Human IL-6, 5G8 | MO-C40091D | 0.1 mg |
| mAb anti-Human IL-6, 1B6 | MO-C40091E | 0.1 mg |
| mAb anti-Human IL-6, 1E3 | MO-C40091F | 0.1 mg |
| mAb anti-Human IL-6, 6D7 | MO-C40091G | 0.1 mg |
| mAb anti-Human IL-6, 9D8 | MO-C40091H | 0.1 mg |
| mAb anti-Human IL-10, 4H2 | MO-C40092A | 0.1 mg |
| mAb anti-Human IL-10, 6D2 | MO-C40092B | 0.1 mg |
| mAb anti Human IL-17A clone 4C1, Capture | MO-C40093A | 0.1mg |
| mAb anti Human IL-17A clone 2F3 | MO-C40093B | 0.1mg |
| mAb anti Human IL-17A clone 8H7 | MO-C40093C | 0.1mg |
| mAb anti Human IL-17A clone 5B4 | MO-C40093D | 0.1mg |
| mAb anti Human IL-17A clone 1E2 | MO-C40093E | 0.1mg |
| mAb anti Human IL-17A clone 2D11 | MO-C40093H | 0.1mg |
| mAb anti Human IL-17A clone 3C1 | MO-C40093I | 0.1mg |
| mAb anti Human IL-17A clone 3H11, Detector | MO-C40093K | 0.1mg |
| mAb anti Human IL-17A clone 5A9 | MO-C40093M | 0.1mg |
| mAb anti Human IL-17A clone 6F12 | MO-C40093O | 0.1mg |
| mAb anti Human IL-17A clone 7F10 | MO-C40093S | 0.1mg |
| mAb anti Human IL-17A clone 10F9 | MO-C40093W | 0.1mg |
| mAb anti Human IL-18 clone 2A10, Capture | MO-C40094A | 0.1mg |
| mAb anti Human IL-18 clone 10H4, Detector | MO-C40094B | 0.1mg |
| mAb anti human IL-18 clone 10H4, Tracer (Biotin Labeled) | MO-C40094TB | 0.1 mL |
| mAb anti Human IL-15 clone 5E8, Capture | MO-C40095A | 0.1mg |
| mAb anti Human IL-15 clone B1H6, Detector | MO-C40095B | 0.1mg |
| mAb anti-human LIF, Clone 2C6 | MO-C40096A | 0.1mg |
| mAb anti-human LIF, Clone 3F4 | MO-C40096B | 0.1mg |
| mAb anti-human LIF, Clone 8B10 | MO-C40096C | 0.1mg |
| mAb anti-DYKDDDDK (Flag) Tag, Flag.10F4 | MO-H40001B | 0.1 mg |
| mAb anti-GAPDH, H8 | MO-H40002A | 0.1 mg |
| mAb anti-HA Tag, HA52 | MO-H40004A | 0.1 mg |
| mAb anti-His Tag, 10A12 | MO-H40005B | 0.1 mg |
| mAb anti-Myc Tag, MycA7 | MO-H40006A | 0.1 mg |
| mAb anti-V5 Tag, V531 | MO-H40007A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 473, Detector | MO-I40002A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 163 | MO-I40002C | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 340, Capture | MO-I40002D2 | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 587, 0.1 mg | MO-I40002E | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 425 | MO-I40002I | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 1027 | MO-I40002J | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 287 | MO-I40002N | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 161 | MO-I40002P | 0.1 mg |
| mAb anti-HBsAg, RM-1 | MO-I40013A | 0.1 mg |
| mAb anti-HCV Core Protein, A1/3D1 | MO-I40015A | 0.1 mg |
| mAb anti-HCV Core Protein, B2 | MO-I40015B | 0.1 mg |
| mAb anti-HCV Core Protein, C3 | MO-I40015E | 0.1 mg |
| mAb anti-HCV NS-4, 7B7/5G9 | MO-I40016B | 0.1 mg |
| mAb anti-HCV NS-4, 5D4/10E7 | MO-I40016D | 0.1 mg |
| mAb anti-HCV NS-4, 7E11 | MO-I40016F | 0.1 mg |
| mAb anti-HCV NS-4, 202 | MO-I40016J | 0.1 mg |
| mAb anti-HCV NS-4, 101 | MO-I40016K | 0.1 mg |
| mAb anti-HCV NS-4, 174 | MO-I40016L | 0.1 mg |
| mAb anti-HCV NS-4, 497 | MO-I40016M | 0.1 mg |
| mAb anti-HCV NS-3, 70-13 | MO-I40018A | 0.1 mg |
| mAb anti-HCV NS-3, 1-5 | MO-I40018B | 0.1 mg |
| mAb anti-HCV NS-3, 12-15 | MO-I40018D | 0.1 mg |
| mAb anti-HCV NS-3, 5-11 | MO-I40018E | 0.1 mg |
| mAb anti-HCV NS-3, 24-8 | MO-I40018F | 0.1 mg |
| mAb anti-HCV NS-3, 20-8 | MO-I40018G | 0.1 mg |
| mAb anti-HCV NS-3, 113 | MO-I40018H | 0.1 mg |
| mAb anti-HCV NS-3, 281 | MO-I40018J | 0.1 mg |
| mAb anti-HCV NS-3, 806 | MO-I40018K | 0.1 mg |
| mAb anti-HCV NS-3, 5 | MO-I40018L | 0.1 mg |
| mAb anti-HCV NS-3, 328 | MO-I40018M | 0.1 mg |
| mAb anti-HCV NS-3, 251 | MO-I40018N | 0.1 mg |
| mAb anti-HCV NS-3, 242 | MO-I40018P | 0.1 mg |
| mAb anti-HCV NS-3, 133 | MO-I40018Q | 0.1 mg |
| mAb anti-HEV, S-13 | MO-I40019B | 0.1 mg |
| mAb anti-HEV, 4H5 | MO-I40019C | 0.1 mg |
| mAb anti-HEV, 2H6 | MO-I40019D | 0.1 mg |
| mAb anti-HEV, 2H2 | MO-I40019E | 0.1 mg |
| mAb anti-HEV, 1B6 | MO-I40019F | 0.1 mg |
| mAb anti-HEV, 5H4 | MO-I40019G | 0.1 mg |
| mAb anti-HP CagA, 10E9, | MO-I40020A | 0.1 mg |
| mAb anti-HP CagA, 5H10 | MO-I40020B | 0.1 mg |
| mAb anti-HP CagA, 5C6 | MO-I40020C | 0.1 mg |
| mAb anti-HP CagA, 3C10, | MO-I40020D | 0.1 mg |
| mAb anti-HP CagA, 3C1 | MO-I40020E | 0.1 mg |
| mAb anti-TB 38KD Antigen, D2G2 | MO-I40021A | 0.1 mg |
| mAb anti-TB 38KD Antigen, C12H11 | MO-I40021B | 0.1 mg |
| mAb anti-TB 38KD Antigen, C11B10 | MO-I40021C | 0.1 mg |
| mAb anti-TB 38KD Antigen, B12F8 | MO-I40021D | 0.1 mg |
| mAb anti-TB 38KD Antigen, A11D2 | MO-I40021E | 0.1 mg |
| mAb anti-TB 38KD Antigen, A2H8 | MO-I40021F | 0.1 mg |
| mAb anti-Human CD3, JXT3 | MO-L40001A | 0.1 mg |
| Rat anti-Mouse CD4, JXYT4 | MO-L40026 | 0.1 mg |
| Rat anti-Mouse CD8, JXYT8 | MO-L40027 | 0.1 mg |
| mAb anti-Human CD11α, A11 | MO-L40028 | 0.1 mg |
| mAb anti-Human HLA-ABC, LY5.1 | MO-L40033 | 0.1 mg |
| mAb anti-Human CD71 Transferrin Receptor, CY-TFR | MO-L40042 | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 1C4 | MO-L40043A | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 7C9, Capture | MO-L40043B | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 9E11 | MO-L40043E | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 9B4 | MO-L40043F | 0.1 mg |
| mAb anti-Human PD-1 / CD279, B1C4 | MO-L40043G | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 7G12, Detector | MO-L40043L | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 2H7 | MO-L40043M | 0.1 mg |
| mAb anti Human PD-L1, clone 6A5 | MO-L40044E | 0.1 mg |
| mAb anti Human PD-L1 clone 8C12 | MO-L40044F | 0.1 mg |
| mAb anti Human PD-L1 clone 12B4, Detector | MO-L40044I | 0.1 mg |
| mAb anti Human PD-L1 clone 11D11 | MO-L40044M | 0.1 mg |
| mAb anti Human PD-L1 clone 15G3, Capture | MO-L40044N | 0.1 mg |
| mAb anti Human PD-L1 clone 12D9 | MO-L40044O | 0.1 mg |
| mAb anti Human PD-L1 clone 15F2 | MO-L40044R | 0.1 mg |
| mAb anti Human PD-L1, clone 10B12 | MO-L40044S | 0.1 mg |
| mAb anti Human CD47, clone 1G10 | MO-L40045A | 0.1 mg |
| mAb anti Human CD47, clone 8H7 | MO-L40045B | 0.1 mg |
| mAb anti Human CD47, clone 9F10 | MO-L40045C | 0.1 mg |
| mAb anti Human CD44, clone 2G7 | MO-L40046A | 0.1 mg |
| mAb anti Human CD44, clone 3C7 | MO-L40046B | 0.1 mg |
| mAb anti-hCG-α, CH5 | MO-M40010A | 0.1 mg |
| mAb anti-hCG-α, CH7 | MO-M40010B | 0.1 mg |
| mAb anti-TRICHOSANTHIN (TCST), TCST-1, 0.1 mg | MO-M40011A | 0.1 mg |
| mAb anti-hGH, YC6, Capture | MO-M40012A | 0.1 mg |
| mAb anti-Human Ig Kappa Light Chain, YCK1 | MO-M40020 | 0.1 mg |
| mAb anti-Human B2MG, D6E4 | MO-M40021B | 0.1 mg |
| mAb anti-Human B2MG, D2E9, Capture | MO-M40021C | 0.1 mg |
| mAb anti-Human B2MG, D6D1 | MO-M40021D | 0.1 mg |
| mAb anti-Human B2MG, D2A10 | MO-M40021E | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Detector | MO-M40021F | 0.1 mg |
| mAb anti-human CRP, 63F4, Capture | MO-M40023A | 0.1 mg |
| mAb anti-human CRP, 67A1 | MO-M40023B | 0.1 mg |
| mAb anti-human CRP, N1G1 | MO-M40023D | 0.1 mg |
| mAb anti-human CRP, S5G1 | MO-M40023E | 0.1 mg |
| mAb Rat anti-Aflatoxin, 1C6, 0.1 mg | MO-M40025A | 0.1 mg |
| mAb Rat anti-Aflatoxin, 1E6, 0.1 mg | MO-M40025B | 0.1 mg |
| mAb Rat anti-Aflatoxin, 2E4 | MO-M40025D | 0.1 mg |
| mAb anti-Human Albumin, S4D6 | MO-M40036 | 0.1 mg |
| mAb anti-Human Factor IX, F9-1, .01 mg | MO-M40037 | 0.1 mg |
| mAb anti-Human Protein C, HLW-C, 0.1 mg | MO-M40038 | 0.1 mg |
| mAb anti-Human Factor X, F10-1, 0.1 mg | MO-M40039 | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 237, 0.1 mg | MO-M40040A | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 474, 0.1 mg | MO-M40040B | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, Y8 | MO-M40040D | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 700 | MO-M40040E | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 585 | MO-M40040F | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 8 | MO-M40040H | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 291 | MO-M40040J | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 262 | MO-M40040N | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 71 | MO-M40040Q | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 128 | MO-M40040S | 0.1 mg |
| mAb anti-Staphylococcal Enterotoxin B [SEB], 0.1 mg | MO-M40041 | 0.1 mg |
| mAb anti-Human PTP1-C, PTY6 | MO-M40043A | 0.1 mg |
| mAb anti-Human PTP1-C, PTY11 | MO-M40043B | 0.1 mg |
| mAb anti-Human PTP1-C, PTY15 | MO-M40043D | 0.1 mg |
| mAb anti-Human PTP1-C, PTY10 | MO-M40043E | 0.1 mg |
| mAb anti-Human PTP1-C, PTY13 | MO-M40043F | 0.1 mg |
| mAb anti-human TSH, TSH-2, Detector | MO-M40046A | 0.1 mg |
| mAb anti-human TSH, TSH-1, Capture | MO-M40046B | 0.1 mg |
| mAb anti-Human Prolactin, PRL-1, Capture | MO-M40047B | 0.5 mg |
| mAb anti-Human LH, LH-1, Capture | MO-M40048B | 0.5 mg |
| mAb anti-hCG, HCG-1, Capture | MO-M40049B | 0.5 mg |
| mAb anti-Human FSH, FSH-1, Capture | MO-M40050B | 0.5 mg |
| mAb anti-Human Raf-1, 410 | MO-M40091E | 0.5 mg |
| mAb anti-Human Raf-1, 540 | MO-M40091G | 0.5 mg |
| mAb anti-Human Raf-1, 863 | MO-M40091J | 0.5 mg |
| mAb anti-Human Raf-1, 163 | MO-M40091M | 0.5 mg |
| mAb anti-Human NSE, 145 | MO-M40092A | 0.5 mg |
| mAb anti-Human NSE, 1G6 | MO-M40092B | 0.5 mg |
| mAb anti-Human NSE, 171 | MO-M40092C | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 3B3 | MO-M40093A | 0.1 mg |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Detector | MO-M40093B | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 3F8 | MO-M40093D | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 3F5 | MO-M40094A | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 1H3 | MO-M40094B | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 6C8 | MO-M40094C | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 5B8, Capture | MO-M40094D | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 4A2 | MO-M40094E | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 7H7 | MO-M40094F | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 5A4 | MO-M40094G | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 4B7 | MO-M40094H | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 7G10 | MO-M40094I | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 1F10 | MO-M40094J | 0.5 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Detector | MO-M40095A | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, CV9 8B2 | MO-M40095B | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, 4B1 | MO-M40095C | 0.1 mg |
| mAb anti-Human α1-antitrypsin, 5G5 | MO-M40096A | 0.1 mg |
| mAb anti-Human α1-antitrypsin, 9F2 | MO-M40096B | 0.1 mg |
| mAb anti-Human α-Synuclein, 4H11 | MO-M40097A | 0.1 mg |
| mAb anti-Human α-Synuclein, 4C1 | MO-M40097B | 0.1 mg |
| mAb anti-Human α-Synuclein, 4B4 | MO-M40097C | 0.1 mg |
| mAb anti-Human α-Synuclein, 8F12 | MO-M40097D | 0.1 mg |
| mAb anti-Human α-Synuclein, 9A9 | MO-M40097E | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, 3E11 | MO-M40098A | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B2B3 | MO-M40098B | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B4H12 | MO-M40098C | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B5B11 | MO-M40098D | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B7B10 | MO-M40098E | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B7H2 | MO-M40098F | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 1A4 | MO-M40099A | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 7G9 | MO-M40099B | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 9B4 | MO-M40099C | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 2A4 | MO-M40099D | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 8E1 | MO-M40100A | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 1G8 | MO-M40100B | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4C1 | MO-M40100C | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 3B12 | MO-M40100D | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4H1 | MO-M40100E | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4H11 | MO-M40100F | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 5C11 | MO-M40100G | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 10G9 | MO-M40100H | 0.1 mg |
| mAb anti-LCRMP4, 5H5 | MO-M40101A | / |
| mAb anti-LCRMP4, 2H7 | MO-M40101B | / |
| mAb anti-LCRMP4 , 7E1 | MO-M40101C | / |
| mAb anti-Human Phospho-STAT5b [p-Y699], A4B9 | MO-P40001A | 0.1 mg |
| mAb anti-Human Phospho-STAT5b [p-Y699], A2H6 | MO-P40001B | 0.1 mg |
| mAb anti-Human Phospho-ELK-1 [p-S383], B4A12 | MO-P40002A | 0.1 mg |
| mAb anti-Human Phospho-ELK-1 [p-S383], D7H2 | MO-P40002B | 0.1 mg |
| mAb anti-Human Phospho-CREB [p-S133], A3A4 | MO-P40003A | 0.1 mg |
| mAb anti-Human Phospho-CREB [p-S133], B1C4 | MO-P40003B | 0.1 mg |
| mAb anti-Human FPRL-1 C-terminal, C4F9 | MO-P40006A | 0.1 mg |
| mAb anti-Human FPRL-1 C-terminal, B4D9B10 | MO-P40006B | 0.1 mg |
| mAb anti-Human FPRL-1 2nd extracellular loop, 3D7 | MO-P40007A | 0.1 mg |
| mAb anti-Human FPRL-1 2nd extracellular loop, B7H10 | MO-P40007B | 0.1 mg |
| mAb anti-Human Lung Carcinoma, CHALU2 | MO-T40005B | 0.1 mg |
| mAb anti-Human Lung Carcinoma, 3504 | MO-T40005C | 0.1 mg |
| mAb anti-Human Hepatocellular Carcinoma, CHALV1 | MO-T40006A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y2, Detector | MO-T40007A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y1, Capture | MO-T40007B | 0.1 mg |
| mAb anti-Human BPH, YBPH-1 | MO-T40008A | 0.1 mg |
| mAb anti-Human BPH, YBPH-2 | MO-T40008B | 0.1 mg |
| mAb anti-Human PML, B3E9 | MO-T40010A | 0.1 mg |
| mAb anti-Human PML, B4C8 | MO-T40010B | 0.1 mg |
| mAb anti-CA 125, 110 | MO-T40012A | 0.1 mg |
| mAb anti-CA 125, 76 | MO-T40012B | 0.1 mg |
| mAb anti-CA 125, 23 | MO-T40012C | 0.1 mg |
| mAb anti-CA 125, 15 | MO-T40012D | 0.1 mg |
| mAb anti-CA 125 | MO-T40012E | 0.1 mg |
| mAb anti-CA50, 93 | MO-T40014A | 0.1 mg |
| mAb anti-CA50, 826 | MO-T40014B | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,8E2 (Free Sample Available) | MO-T40015A | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,9B2 (Free Sample Available) | MO-T40015B | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,1A5 (Free Sample Available) | MO-T40015C | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,4E11 (Free Sample Available) | MO-T40015D | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,9E1 (Free Sample Available) | MO-T40015E | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,7C4 (Free Sample Available) | MO-T40015F | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,7E6 (Free Sample Available) | MO-T40015G | 0.1 mg |
| mAb anti-Human Colorectal Carcinoma, Y94 | MO-T40022 | 0.1 mg |
| mAb anti-Human Colorectal Carcinoma/CD3, BS-1 | MO-T40035 | 0.1 mg |
| mAb anti-Human CEA, CEA-Y2, Detector | MO-T40051A | 0.1 mg |
| mAb anti-Human CEA, CEA-Y1, Capture | MO-T40051B | 0.1 mg |
| mAb anti-Human Free PSA, 103, Detector | MO-T40052A | 0.1 mg |
| mAb anti-Human Free PSA, 108, Capture | MO-T40052B | 0.1 mg |
| mAb anti-Human PSA, CHYH1, Capture | MO-T40081A | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Dectector | MO-T40081B | 0.1 mg |
| mAb anti-Human PMA, YPMA-1 | MO-T40083A | 0.1 mg |
| mAb anti-Human PMA, YPMA-2 | MO-T40083B | 0.1 mg |
| mAb anti-Human PSP, YPSP-1 | MO-T40085A | 0.1 mg |
| mAb anti-Human PSP, YPSP-2 | MO-T40085B | 0.1 mg |
| mAb anti-Human PSP, YPSP-3 | MO-T40085C | 0.1 mg |
| mAb anti-Human PSP, YPSP-4 | MO-T40085D | 0.1 mg |
| mAb anti-Human PSMA, YPSMA-1 | MO-T40086A | 0.1 mg |
| mAb anti-Human PSMA, YPSMA-2 | MO-T40086B | 0.1 mg |
| mAb anti-Human PSMA, 4H11 | MO-T40086C | 0.1 mg |
| mAb anti-Human PSMA, 7F3 | MO-T40086D | 0.1 mg |
| mAb anti-Human PTMA, 8H12 | MO-T40087A | 0.1 mg |
| mAb anti-Human PTMA, 9A10 | MO-T40087B | 0.1 mg |
| mAb anti-Human PTMA, 6A3 | MO-T40087C | 0.1 mg |
| mAb anti-Human PTMA, 4G2 | MO-T40087D | 0.1 mg |
| mAb anti-Human PTMA, 5A10 | MO-T40087E | 0.1 mg |
| mAb anti-Human PTMA, 6H7 | MO-T40087F | 0.1 mg |
| mAb anti-Human PTMA, 1F2, Capture | MO-T40087G | 0.1 mg |
| mAb anti-Human PTMA, 4C3 | MO-T40087H | 0.1 mg |
| mAb anti-Human PTMA, 4A7, Detector | MO-T40087I | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9A4 | MO-T40088A | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2E6 | MO-T40088B | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 1A10 | MO-T40088C | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 5C2 | MO-T40088D | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 10H9 | MO-T40088E | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2A3 | MO-T40088F | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2E5 | MO-T40088G | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 5H12 | MO-T40088H | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9C7 | MO-T40088I | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9D5 | MO-T40088J | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 3E7 | MO-T40088K | 0.1 mg |
| Human PSA ELISA Kit | EL10005 | 96 wells |
| Human IL-8 ELISA Kit | EL10008 | 96 wells |
| Human MCAF / MCP-1 ELISA Kit | EL10009 | 96 wells |
| Human EGF ELISA Kit | EL10010 | 96 wells |
| Human LH ELISA Kit | EL10011 | 96 wells |
| Human TSH ELISA Kit | EL10012 | 96 wells |
| Neonatal TSH ELISA Kit | EL10012N | 96 wells |
| Ultra-Sensitive Human TSH ELISA Kit | EL10012U | 96 wells |
| Human FSH ELISA Kit | EL10013 | 96 wells |
| Human Prolactin ELISA Kit | EL10014 | 96 wells |
| Human SAA ELISA Kit | EL10015 | 96 wells |
| Human SAA ELISA Kit (2nd Generation) | EL10015L | 96 wells |
| Human MCP-3 ELISA Kit | EL10016 | 96 wells |
| Human TNF-α ELISA Kit | EL10019 | 96 wells |
| Human GM-CSF ELISA Kit | EL10020 | 96 wells |
| Human IL-16 ELISA Kit | EL10021 | 96 wells |
| High Sensitivity Human CRP ELISA Kit | EL10022hs | 96 wells |
| Human IL-6 ELISA Kit | EL10023 | 96 wells |
| Human IFN-γ ELISA Kit | EL10024 | 96 wells |
| Human IL-2 ELISA Kit | EL10025 | 96 wells |
| Human IL-4 ELISA Kit | EL10026 | 96 wells |
| Human IL-10 ELISA Kit | EL10027 | 96 wells |
| Human IL-1β ELISA Kit | EL10028 | 96 wells |
| Human TGF-β1 ELISA Kit | EL10029 | 96 wells |
| Human Growth Hormone (hGH) ELISA Kit/Hormone Elisa | EL10030 | 96 wells |
| High Sensitivity Human Growth Hormone (H-hGH) ELISA Kit | EL10030H | 96 wells |
| Human Chorionic Gonadotropin (hCG) ELISA Kit | EL10031 | 96 wells |
| Human IL-12 (P70) ELISA Kit | EL10032 | 96 wells |
| Human IL-2 sRα ELISA Kit | EL10033 | 96 wells |
| Human IL-6 sR ELISA Kit | EL10034 | 96 wells |
| Human IL-5 ELISA Kit | EL10035 | 96 wells |
| HAMA ELISA Kit | EL10036 | 96 wells |
| Human IL-13 Rα2 ELISA Kit | EL10039 | 96 wells |
| Human IL-1α ELISA Kit | EL10040 | 96 wells |
| Human IL-7 ELISA Kit | EL10041 | 96 wells |
| Human IL-11 ELISA Kit | EL10042 | 96 wells |
| Human IL-15 ELISA Kit | EL10044 | 96 wells |
| Human M-CSF ELISA Kit | EL10046 | 96 wells |
| Human TNF-β ELISA Kit | EL10047 | 96 wells |
| Human bFGF ELISA Kit | EL10048 | 96 wells |
| Human Alphafetoprotein (AFP) ELISA Kit | EL10049 | 96 wells |
| Human B2MG ELISA Kit | EL10051 | 96 wells |
| Human Carcinoembryonic Antigen (CEA) ELISA Kit | EL10052 | 96 wells |
| Human IL-17A ELISA Kit | EL10053 | 96 wells |
| Human IL-13 ELISA Kit | EL10054 | 96 wells |
| Human IL-22 ELISA Kit | EL10055 | 96 wells |
| Human IL-9 ELISA Kit | EL10056 | 96 wells |
| Human Amyloid Beta Peptide 42 ELISA Kit | EL10057 | 96 wells |
| Human Programmed Death-Ligand 1 (PD-L1) ELISA Kit | EL10058 | 96 wells |
| Human Programmed Death-1 (PD-1) ELISA Kit | EL10059 | 96 wells |
| Human IL-18 ELISA Kit | EL10060 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (Inflammatory) | EM10001 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (M1/M2/MDSC Cytokines) | EM10002 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (Th1/Th2/Th17) | EM10003 | 96 wells |
| Mouse IL-17A ELISA Kit | MEC1001 | 96 wells |
| Mouse IFN-γ ELISA Kit | MEC1002 | 96 wells |
| Mouse TNF-α ELISA Kit | MEC1003 | 96 wells |
| Mouse GM-CSF ELISA Kit | MEC1004 | 96 wells |
| Mouse MCP-1 ELISA Kit | MEC1005 | 96 wells |
| Mouse IL-2 ELISA Kit | MEC1006 | 96 wells |
| Mouse IL-5 ELISA Kit | MEC1007 | 96 wells |
| Mouse IL-6 ELISA Kit | MEC1008 | 96 wells |
| Mouse IL-4 ELISA Kit | MEC1009 | 96 wells |
| Mouse IL-1β ELISA Kit | MEC1010 | 96 wells |
| Mouse IL-1α ELISA Kit | MEC1011 | 96 wells |
| Mouse TGF-β1 ELISA Kit | MEC1012 | 96 wells |
| pAb anti-Human CRP, Tracer (HRP Labeled) | AI20009P | 0.2 mL |
| mAb anti-Human TNF-α, CH8820, Capture | MO-C40003B | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Detector | MO-C40003E | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Tracer (HRP Labeled) | MO-C40003T | 0.2 mL |
| mAb anti-Human TNF-α, B1E4, Tracer (Biotin Labeled) | MO-C40003TB | 0.1 mL |
| mAb anti-Human IL-8, I8-S2, Capture | MO-C40017A | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Detector | MO-C40017D | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Tracer (HRP Labeled) | MO-C40017T | 0.2 mL |
| mAb anti-Human IL-8, I8-60, Tracer (Biotin Labeled) | MO-C40017TB | 0.1 mL |
| mAb anti-Human MCP-1, S14, Capture | MO-C40021B | 0.1 mg |
| mAb anti-Human MCP-1, S101, Detector | MO-C40021D | 0.1 mg |
| mAb anti-Human MCP-1, S101, Tracer (HRP Labeled) | MO-C40021T | 0.2 mL |
| mAb anti-Human MCP-1, S101, Tracer (Biotin Labeled) | MO-C40021TB | 0.1 mL |
| mAb anti-Human SAA, 115, Capture | MO-C40028A | 0.1 mg |
| mAb anti-Human SAA, 607, Detector | MO-C40028E | 0.1 mg |
| mAb anti-Human SAA, 607, Tracer (HRP Labeled), 0.2mL | MO-C40028T | 0.2 mL |
| mAb anti-Human SAA, 607, Tracer (Biotin Labeled), 0.1mL | MO-C40028TB | 0.1 mL |
| mAb anti-Human EGF, S-134, Capture | MO-C40044D | 0.1 mg |
| mAb anti-Human EGF, S-146, Detector | MO-C40044F | 0.1 mg |
| mAb anti-Human EGF, S-146, Tracer (HRP Labeled) | MO-C40044T | 0.2 mL |
| mAb anti-Human EGF, S-146, Tracer (Biotin Labeled) | MO-C40044TB | 0.1 mL |
| mAb anti-Human MCP-3, 113, Detector | MO-C40088A | 0.1 mg |
| mAb anti-Human MCP-3, 542, Capture | MO-C40088G | 0.1 mg |
| mAb anti-Human MCP-3, 113, Tracer (HRP Labeled) | MO-C40088T | 0.2 mL |
| mAb anti-Human MCP-3, 113, Tracer (Biotin Labeled) | MO-C40088TB | 0.1 mL |
| mAb anti-Human IL-16, 323, Detector | MO-C40089J | 0.1 mg |
| mAb anti-Human IL-16, 398, Capture | MO-C40089K | 0.1 mg |
| mAb anti-Human IL-16, 323, Tracer (HRP Labeled) | MO-C40089T | 0.2 mL |
| mAb anti-Human GM-CSF, 59, Capture | MO-C40090B | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Detector | MO-C40090D | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Tracer (HRP Labeled) | MO-C40090T | 0.2 mL |
| mAb anti-Human GM-CSF, 429, Tracer (Biotin Labeled) | MO-C40090TB | 0.1 mL |
| mAb anti Human IL-18 clone 2A10, Capture | MO-C40094A | 0.1mg |
| mAb anti Human IL-18 clone 10H4, Detector | MO-C40094B | 0.1mg |
| mAb anti human IL-18 clone 10H4, Tracer (Biotin Labeled) | MO-C40094TB | 0.1 mL |
| mAb anti Human IL-15 clone 5E8, Capture | MO-C40095A | 0.1mg |
| mAb anti Human IL-15 clone B1H6, Detector | MO-C40095B | 0.1mg |
| mAb anti human IL-15 clone B1H6, Tracer (Biotin labeled) | MO-C40095TB | 0.1 mL |
| mAb anti-HIV-1 P24 (Core Protein), 473, Detector | MO-I40002A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 340, Capture | MO-I40002D2 | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 473, Tracer (HRP), 0.2 mL | MO-I40002T2 | 0.2 mL |
| mAb anti-Human PD-1 / CD279, 7G12, Tracer (Biotin labeled) | MO-L40043TB | 0.1 mL |
| mAb anti Human PD-L1 clone 12B4, Detector | MO-L40044I | 0.1 mg |
| mAb anti Human PD-L1 clone 15G3, Capture | MO-L40044N | 0.1 mg |
| mAb anti human PD-L1 clone 12B4, Tracer (Biotin Labeled) | MO-L40044TB | 0.1 mL |
| mAb anti-hGH, YC6, Capture | MO-M40012A | 0.1 mg |
| mAb anti-hGH, YC8, Tracer (HRP Labeled), 0.2 mL | MO-M40012T | 0.2 mL |
| mAb anti-hGH, YC8, Tracer (Biotin Labeled), 0.1 mL | MO-M40012TB | 0.1 mL |
| mAb anti-Human B2MG, D2E9, Capture | MO-M40021C | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Detector | MO-M40021F | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Tracer (HRP Labeled), 0.2mL | MO-M40021T | 0.2 mL |
| mAb anti-human CRP, 63F4, Capture | MO-M40023A | 0.1 mg |
| mAb anti-human TSH, TSH-2, Detector | MO-M40046A | 0.1 mg |
| mAb anti-human TSH, TSH-1, Capture | MO-M40046B | 0.1 mg |
| mAb anti-human TSH, TSH-2, Tracer (HRP Labeled), 0.2 mL | MO-M40046T | 0.2 mL |
| mAb anti-Human Prolactin, PRL-1, Capture | MO-M40047B | 0.5 mg |
| mAb anti-Human Prolactin, PRL-2, Tracer (HRP Labeled), 0.2 mL | MO-M40047T | 0.2 mL |
| mAb anti-Human LH, LH-1, Capture | MO-M40048B | 0.5 mg |
| mAb anti-Human LH, LH-2, Tracer (HRP Labeled), 0.2 mL | MO-M40048T | 0.2 mL |
| mAb anti-hCG, HCG-1, Capture | MO-M40049B | 0.5 mg |
| mAb anti-hCG, HCG-2, Tracer (HRP Labeled), 0.2 mL | MO-M40049T | 0.2 mL |
| mAb anti-Human FSH, FSH-1, Capture | MO-M40050B | 0.5 mg |
| mAb anti-Human FSH, FSH-2, Tracer (HRP Labeled) | MO-M40050T | 0.2 mL |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Detector | MO-M40093B | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Tracer (Biotin) | MO-M40093TB | 0.1 mL |
| mAb anti-Amyloid β Peptide N-terminal, NT 5B8, Capture | MO-M40094D | 0.5 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Detector | MO-M40095A | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Tracer (Biotin) | MO-M40095TB | 0.1 mL |
| mAb anti-Human AFP, AFP-Y2, Detector | MO-T40007A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y1, Capture | MO-T40007B | 0.1 mg |
| mAb anti-Human AFP, AFP-2, Tracer (HRP Labeled), 0.2 mL | MO-T40007T | 0.2 mL |
| mAb anti-Human CEA, CEA-Y2, Detector | MO-T40051A | 0.1 mg |
| mAb anti-Human CEA, CEA-Y1, Capture | MO-T40051B | 0.1 mg |
| mAb anti-Human CEA, CEA-Y2, Tracer (HRP Labeled), 0.2 mL | MO-T40051T | 0.2 mL |
| mAb anti-Human Free PSA, 103, Detector | MO-T40052A | 0.1 mg |
| mAb anti-Human Free PSA, 108, Capture | MO-T40052B | 0.1 mg |
| mAb anti-Human Free PSA, 103, Tracer (HRP Labeled), 0.2 mL | MO-T40052T | 0.2 mL |
| mAb anti-Human PSA, CHYH1, Capture | MO-T40081A | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Dectector | MO-T40081B | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Tracer (HRP Labeled), 0.2 mL | MO-T40081T | 0.2 mL |
| Human Chorionic Gonadotrophin (hCG), 10 mg | AP30002 | 10 mg |
| Human Immunoglobulin G (IgG), 10 mg | IG30001 | 10 mg |
| Mouse Immunoglobulin G (IgG), 10 mg | IG41002 | 10 mg |
| Mouse Immunoglobulin G2b (IgG2b), 10 mg | IG41004 | 10 mg |
| Rat Immunoglobulin G (IgG) | IG42003 | 10 mg |
| Human Umbilical Cord Serum, 10 mL | S30010 | 10 mL |
| ELISA Coating (EC) Stabilizer, 500 mL | S7001 | 500 mL |
| Human IL-8 Matched Antibody Pair for ELISpot | SL10008A | 5 × 96 wells |
| Human IL-8 Development Set for ELISpot | SL10008B | 5 × 96 wells |
| Human IL-8 ELISpot Kit | SL10008E | 6 X 96 wells |
| Human MCAF (MCP-1) Matched Antibody Pair for ELISpot | SL10009A | 5 × 96 wells |
| Human MCAF (MCP-1) Development Set for ELISpot | SL10009B | 5 × 96 wells |
| Human MCAF (MCP-1) ELISpot Kit | SL10009E | 6 X 96 wells |
| Human GM-CSF Matched Antibody Pair for ELISpot | SL10020A | 5 × 96 wells |
| Human GM-CSF Development Set for ELISpot | SL10020B | 5 × 96 wells |
| Human GM-CSF ELISpot Kit | SL10020E | 6 X 96 wells |
| Human IFN-γ Matched Antibody Pair for ELISpot | SL10024A | 5 × 96 wells |
| Human IFN-γ Development Set for ELISpot | SL10024B | 5 × 96 wells |
| Human IFN-γ ELISpot Kit | SL10024E | 6 X 96 wells |
| Human IL-12 (P70) ELISpot Kit | SL10032E | 6 X 96 wells |
| TMB Solution (500 mL Part A & 500 mL Part B) | SU6006 | 1.0 L |
| pAb Rabbit anti-HCV Virus, 1.0 mg | AI20006P | 1.0 mg |
| pAb Rabbit anti-HIV-1 p24, 1.0 mg | AI20008P | 1.0 mg |
| pAb anti-Human CRP, Tracer (HRP Labeled) | AI20009P | 0.2 mL |
| pAb Rabbit anti-Mouse IgG , 1.0 mg | AI50005 | 1.0 mg |
| pAb Rabbit anti-Mouse IgG - HRP Conjugated, 1.0 mL | AI50005P | 1.0 mL |
| pAb Rabbit anti-hGH, | AI50006P | 1.0 mg |
| pAb Chicken anti-human IL-8 (IgY fraction) | AI60001 | 1.0 mg |
| pAb Rabbit anti-Human FPRL-1 2nd Extracellular Loop | AI70001A | 0.1 mg |
| pAb Rabbit anti-Human FPRL-1 C-terminal | AI70001B | 0.1 mg |
| pAb Rabbit anti-Human PML [Ring Finger Domain] | AI70002A | 0.1 mg |
| pAb Rabbit anti-Human PML [B-box 1 domain] | AI70002B | 0.1 mg |
| pAb Rabbit anti-Bcl-2 | AI70003A | 0.1 mg |
| pAb Rabbit anti-Phospho-Bcl-2 (Thr56) | AI70003B | 0.1 mg |
| pAb Rabbit anti-Phospho-Bcl-xL (Thr115) | AI70003D | 0.1 mg |
| pAb Rabbit anti-Phospho c-kit (Tyr719) | AI70004A | 0.1 mg |
| pAb Rabbit anti-Phospho IKK-γ (Ser31) | AI70005A | 0.1 mg |
| pAb Rabbit anti-NF-κB-p65 (RelA) | AI70006A | 0.1 mg |
| pAb Rabbit anti-Phospho-NF-қB-p65 (Ser276) | AI70007A | 0.1 mg |
| pAb Rabbit anti-Phospho-NF-қB-p65 (Ser468) | AI70008A | 0.1 mg |
| pAb Rabbit anti-Phospho NF-қB-p105/p50 (Ser337) | AI70009A | 0.1 mg |
| pAb Rabbit anti-Human Serum Albumin (HSA) | AI80001 | 0.1 mg |
| pAb Rabbit anti-Human Fibrinogen, 0.1 mg | AI80002 | 0.1 mg |
| pAb Rabbit anti-Human Transferrin | AI80003 | 0.1 mg |
| pAb Rabbit anti-Human IgA, 0.5 mg | AI80004 | 0.5 mg |
| pAb Rabbit anti-human IgM, 0.5 mg | AI80005 | 0.5 mg |
| pAb Rabbit anti-Human TREK-1 (K2p2.1) | AI80006A | 0.1 mg |
| pAb Rabbit anti-Mouse Kchip1 | AI80007 | 0.1 mg |
| pAb Rabbit anti-Mouse Kchip4 | AI80008 | 0.1 mg |
| pAb Rabbit anti-Mouse Kv4.3 | AI80010A | 0.1 mg |
| pAb Rabbit anti-Mouse TRPV1 | AI80011A | 0.1 mg |
| pAb Rabbit anti-Mouse TRPV3 | AI80012A | 0.1 mg |
| pAb Rabbit anti-Human JAK2 | AI80013A | 0.1 mg |
| pAb Rabbit anti-Human Glutathione S Transferase (GST), 0.1 mg | AI80014 | 0.1 mg |
| pAb Rabbit anti-Human Amyloid beta peptide 42 | AI90001 | 0.1 mg |
| pAb Rabbit anti-Human Amyloid beta peptide 43 | AI90002 | 0.1 mg |

艾美捷科技特约代理Biogems产品。
BioGems意为生物钻石,其产品涵盖多种荧光标记的流式抗体、具有生物活性的功能性抗体,以及流式细胞术辅助试剂,如溶血剂和破膜剂等。BioGems产品全部在美国生产,目前已拥有超过500种流式试剂和600余种重组蛋白产品。
Through the establishment of joint collaborations with reputable manufacturers of top-quality life-science research products such as PeproTech Inc., BioGems has positioned itself to become a highly competitive source for a wide-range of recombinant protein and flow-cytometry reagents. Currently, our catalog contains more than 600 recombinant proteins and over 500 flow cytometry reagents. To keep up with the rapidly advancing research fronts, BioGems continuously adds new products to its catalog. All of our products are subjected to a thorough and rigorous quality and performance testing to ensure that each and every product meets the highest established standards. Providing our customers with the highest-quality products at affordable prices is our goal. We are confident that the unique business arrangements of BioGems together with our highly skilled and experienced personnel will enable us to achieve this goal.
主要产品分类:
(1)Flow Cytometry
Conjugated Antibodies
SAFIRE Functional Antibodies
Isotype Controls
Custom and Bulk Reagents
Purified Antibodies
Buffers and Solutions
(2)Recombinant Proteins
Growth Factors & Cytokines
Animal-Free Cytokines
Chemokines
Neurotrophins
Other Proteins
Anti Cytokine & Chemokine Antibodies
(3)Small Molecules
Receptor Antagonist and Inhibitors
Receptor Agonists and Activators
(4)Pre-Coated Elisa Kits
Human
Mouse
Rat
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="BioGems"> BioGems
艾美捷科技代理Avanti Polar Lipids全系列产品。
Avanti Polar Lipids公司是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供 1000 种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,Avanti Polar Lipids公司为世界各地的研究人员和制药公司提供脂类产品。
Avanti Polar Lipids, Inc., has a long history of 50 years creating the highest purity lipids available. Our passion for high quality and unique products is only exceeded by our excellent reputation in the marketplace. Although we are known for our lipids, we are More than Lipids. We offer solutions for the entire product cycle…Research to Commercialization.
Avanti Polar Lipids公司的主要产品和服务包括:
(1)Research Products
Highest Purity Lipid Reagents
(2)cGMP Manufacturing
API & Contract Manufacturing
(3)Adjuvants
Immunotherapy & Vaccine Development
(4)Analytical Services
Lipid Analysis
(5)Lipidomics
Mass Spec Standards, Antibodies & Lipid Toolbox
(6)Formulations
Liposomes & Nanoparticles
(7)Equipment
Liposome Production Tools
(8)Custom Services
Synthesis & Beyond
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Avanti Polar Lipids"> Avanti Polar Lipids
Stemmera公司位于美国加州,主要生产干细胞相关产品,包括检测试剂盒、培养基、抗体、缓冲液,还包括用于干细胞研究的细胞系。
Stemmera Inc is a privately owned biotechnology company located in Bay Area, California that focus in developing innovative technology and application solution for stem cell research. Our products include kit, culture medium, reagents, antibodies, buffer and solution, cell lines that are convenient tools used in stem cell research.
Stemmera公司主要产品:
(1)Kit
Alkaline Phosphatase (AP) Detection Kit (Ready-to-use)-Blue
Alkaline Phosphatase (AP) Detection Kit (Ready-to-use)-Red
Human Fibroblast (hFIB) Reprogramming Kit
Human Blood Cell (hBLD) Reprogramming Kit
(2)Media
Human ESCs/iPSCs Serum-/ Feeder-Free Medium (hStemSFM)
Human ESCs/iPSCs Xeno-Free Medium (hStemXFM)
Human Fibroblast (hFIB) Reprogramming Medium
Human Blood Cell (hBLD) Reprogramming Medium
Fibroblast Growth Medium
(3)Buffer & Solutions
Non-Enzymatic Cell Dissociation Solution (1X)
Serum-Free Cryopreservation Solution for Human ESCs/iPSCs
0.2% Gelatin
0.1% Gelatin
Universal Cryopreservation Solution
Blood Cell Cryopreservation Solution (1x)
Cell Fixation Solution (4% Paraformaldehyde, PFA)
Cell Fixation Solution (10% Formalin)
Metaphase Arrest Solution (10 μg/ml, 10X)
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Stemmera"> Stemmera
艾美捷科技特约代理BioPAL全系列产品。
BioPAL公司位于美国马萨诸塞Worcester,服务于生命科学和生物医药行业,主要从事非放射性报告系统的研发、生产、商业化。此外,BioPAL销售用于核磁共振(MRI)的纳米颗粒;BioPAL还提供即用型的细胞标记及示踪产品。
BioPhysics Assay Laboratory (BioPAL, Inc.) is a privately held, for-profit company based in Worcester Massachusetts. The company develops and sells novel tools for the life science and biomedical communities. BioPAL was the first company to commercialize non-radioactive products that use neutron activation technology as the read-out system. The company also develops and sells nanoparticles for applications in magnetic resonance imaging (MRI), magnetic separation applications and tools for time resolved fluorescent technology. BioPAL offers ready-to-use cell labeling and tracking products for cellular therapy research applications.
BioPAL was the first to introduce functional immunoassay technology (FIT) to the research community. The company offers a line of renal diagnostics based on FIT to measure glomerular filtration rate (GFR) and effective renal blood flow (RBF). Most notably is BioPAL's ELISA kit for the measurement of inulin.
BioPAL公司的主要产品包括:
Pre-Clinical Imaging Agents
Kidney Diagnostics
Microspheres for Blood Flow Studies
Dead-Cell Removal Kits - Viahanc
Products for Cellular Therapy Research
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理BioPAL全系列产品"> 艾美捷科技特约代理BioPAL全系列产品
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18327026838
传真:18771149750
邮箱:sales@amyjet.com
0.3579